The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital

  title={The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital},
  author={C. Antoniou and I. Stefanaki and A. Stratigos and G. Avgerinou and P. Stavropoulos and I. Potouridou and D. Polidorou and A. Moustou and M. Kosmadaki and A. Katsambas},
  journal={British Journal of Dermatology},
Background  Efalizumab (anti‐CD11a antibody) targets T cell‐mediated steps important in the immunopathogenesis of psoriasis. As efalizumab is intended to be administered on a continuous long‐term basis in psoriasis, it is important to share experience concerning issues commonly occurring during its use in real daily practice. 
Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice
Background.  Efalizumab is approved by the European Medicines Evaluation Agency for the treatment of adult patients with moderate to severe plaque psoriasis who fail to respond to, have aExpand
Efalizumab-associated papular psoriasis: An adverse reaction to efalizumab in three cases
Three cases of efalizumab-associated papular psoriasis are reported, characterized by a transient popular eruption localized especially on the flexural areas and on the back. Expand
Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis
The classic regimen currently used at the institution includes dermal application of 2% crude coal tar three times daily and exposure to incremental doses of broad-band ultraviolet B (UVB) radiation, 7 days a week, as described previously. Expand
Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre
Large‐scale clinical trials provide clear evidence of the efficacy and short‐term toxicity of biologic therapies for psoriasis, but there are few reports of the practical use of these therapies outside of the trial setting and, to the authors' knowledge, none from a U.K. cohort of patients with Psoriasis. Expand
Eczematous Dermatosis and Thrombocytosis Induced by Efalizumab: Two New Side Effects
2 adverse events under efalizumab that to the knowledge have never been described are reported: a case of an eczematous rash and a cases of thrombocytosis. Expand
Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis.
A considerable body of data indicates that efalizumab is an appropriate alternative to other biologic or nonbiologic therapies for the treatment of chronic moderate-to-severe plaque psoriasis that, additionally, offers the potential convenience of self-injection at home. Expand
[Biological therapy for psoriasis: practical experience at a French dermatology unit].
The study confirms the efficacy and feasibility of BT in clinical practice, however, the high frequency of BT discontinuation for adverse events or non-response led to sequential therapy using different biological treatments. Expand
[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
The safety data provided by the study should be taken into account in view of the large number of patients recruited by dermatologists experienced in the use of this type of therapy, particularly with regard to their safety. Expand
Risk of Herpes zoster in patients with psoriasis treated with biologic drugs
This data indicates that among patients with psoriasis treated with biologic drugs, herpes zoster (HZ) is more common than previously thought, and the risk of serious adverse events, including death, is higher than in patients treated with conventional treatments. Expand
Efalizumab: ¿un tratamiento seguro para una enfermedad crónica?
The potential risks involved in treatment with efalizumab, specifically the acute flu-like syndrome, alterations in laboratory data, infections, neoplasms, skin disorders related with psoriasis, joint manifestations, acute inflammatory polyradiculoneuropathy and hypersensitivity reactions are reviewed. Expand


T-Cell Modulation for the Treatment of Chronic Plaque Psoriasis with Efalizumab (Raptiva™): Mechanisms of Action
The pharmacodynamic, pharmacokinetic and clinical effects observed during phase I, II and III efalizumab trials in patients with moderate to severe chronic plaque psoriasis are reviewed. Expand
Clinical considerations of efalizumab therapy in patients with psoriasis.
  • T. Hamilton
  • Medicine
  • Seminars in cutaneous medicine and surgery
  • 2005
Clinical trial data and case reports illustrate recommended patient management techniques and the substantial long-term benefits that psoriasis patients may realize with efalizumab therapy. Expand
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
The present review of the available Phase III clinical trial suggests that efalizumab is not associated with an increased risk for infection in patients receiving initial or long-term treatment for moderate to severe chronic plaque psoriasis. Expand
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
These results suggest that efalizumab maintains, and in some patients continues to improve, efficacy during long-term therapy. Expand
Relapse, rebound, and psoriasis adverse events: an advisory group report.
After publication of the NPF definition of rebound, post hoc exploratory analyses of the efalizumab clinical trial data were performed and investigators discussed their observations, the analyses, and their individual approaches to the treatment of patients receiving or discontinuing efalIZumab therapy. Expand
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction.
The impact of psoriasis on quality of life has been studied in select patient populations. Population-based data detailing the distribution of extent of disease, associated problems in everyday life,Expand
Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis
Findings confirm endothelial proliferation underlying psoriatic microvascular expansion, and indicate that this process is limited to a specific site in the dermal capillary bed. Expand
[On the treatment of psoriasis].
  • A. Vaag
  • Medicine
  • Ugeskrift for laeger
  • 1962